Perritt Capital Management Inc. cut its holdings in ImmuCell Co. (NASDAQ:ICCC) by 15.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 130,000 shares of the biotechnology company’s stock after selling 23,000 shares during the quarter. Perritt Capital Management Inc. owned about 1.80% of ImmuCell worth $845,000 as of its most recent SEC filing.

Separately, Ingalls & Snyder LLC boosted its position in shares of ImmuCell by 5.2% during the 2nd quarter. Ingalls & Snyder LLC now owns 96,243 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 4,732 shares in the last quarter. 23.08% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:ICCC traded up $0.26 on Wednesday, reaching $5.51. 700 shares of the company traded hands, compared to its average volume of 4,547. ImmuCell Co. has a fifty-two week low of $5.15 and a fifty-two week high of $9.30. The company’s 50 day moving average is $5.81 and its 200-day moving average is $6.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 8.22 and a quick ratio of 6.76.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 6.84% and a negative net margin of 14.61%. The company had revenue of $2.71 million during the quarter.

A number of research firms recently commented on ICCC. TheStreet downgraded shares of ImmuCell from a “c-” rating to a “d” rating in a report on Wednesday, September 4th. ValuEngine upgraded shares of ImmuCell from a “hold” rating to a “buy” rating in a report on Thursday, September 5th.

ImmuCell Profile

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

Featured Story: Balanced Fund

Want to see what other hedge funds are holding ICCC? Visit to get the latest 13F filings and insider trades for ImmuCell Co. (NASDAQ:ICCC).

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.